Marja T. Nevalainen, MD, PhD

Professor, Eminent Scholar, Department of Pathology and Pharmacology & Toxicology; Assistant Dean of Research, Medical College of Wisconsin; Associate Director (Education), Medical College of Wisconsin Cancer Center; Director, Prostate Cancer Center of Excellence at Medical College of Wisconsin Cancer Center

Contact Information

Education

University of Turku, School of Medicine, Turku, Finland, MD
University of Turku, Turku, Finland, Cell Biology, PhD

Biography

Marja Nevalainen, MD, PhD is an internationally recognized leader in the field of cytokine and steroid hormone signaling in prostate cancer. The focus of her laboratory is on translational prostate cancer research to develop and improve diagnostics and therapy for prostate cancer. Dr. Nevalainen holds the title of Eminent Scholar at MCW. She is also Director of Prostate Cancer Center of Excellence at MCW Cancer Center, which is a multi-disciplinary hub for prostate cancer research within the institution with an international collaborative network. Dr. Nevalainen serves as Assistant Dean for Research at MCW, and Associate Director of Education for the MCW Cancer Center. Her primary appointment is in the Department of Pathology, and a secondary appointment in the Department of Pharmacology and Toxicology. Dr. Nevalainen has extensive experience in collaborative research, mentoring and leadership from her previous roles at Sidney Kimmel Cancer Center at Thomas Jefferson University as Associate Director of Education and Vice Chair of Education in the Department of Cancer Biology.

Honors and Awards

General Medicine Board Certification

Research Interests

Jak-Stat signaling
Prostate cancer progression
Therapy development
Companion diagnostics
Predictive Factors
DNA repair
Radiation therapy
In vitro and in vivo models
3D tumor explant culture
Epithelial-mesenchymal transition
Cancer stem-like cell properties
Metastases models
Small molecule therapeutics

Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer

(Maisel BA, Yi M, Peck AR, Sun Y, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Nevalainen MT, Tanaka T, Simone N, Wang LL, Rui H, Chervoneva I.) Cancers. January-2 2022;14(2) SCOPUS ID: 2-s2.0-85122409008 01/01/2022
Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.

(McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, Quarles CC, Prah MA, Schmainda KM, Taouli B, LoCastro E, Mazaheri Y, Shukla-Dave A, Yankeelov TE, Hormuth DA 2nd, Madhuranthakam AJ, Hulsey K, Li K, Huang W, Huang W, Muzi M, Jacobs MA, Solaiyappan M, Hectors S, Antic T, Paner GP, Palangmonthip W, Jacobsohn K, Hohenwalter M, Duvnjak P, Griffin M, See W, Nevalainen MT, Iczkowski KA, LaViolette PS.) J Magn Reson Imaging. 2021 Nov 12 PMID: 34767682 SCOPUS ID: 2-s2.0-85118887092 11/13/2021
Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

(Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT.) Cancers (Basel). 2021 Oct 17;13(20) PMID: 34680353 PMCID: PMC8533841 10/24/2021
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.

(Sun Y, Yang N, Utama FE, Udhane SS, Zhang J, Peck AR, Yanac A, Duffey K, Langenheim JF, Udhane V, Xia G, Peterson JF, Jorns JM, Nevalainen MT, Rouet R, Schofield P, Christ D, Ormandy CJ, Rosenberg AL, Chervoneva I, Tsaih SW, Flister MJ, Fuchs SY, Wagner KU, Rui H.) Sci Adv. 2021 Sep 17;7(38):eabc8145 PMID: 34524841 PMCID: PMC8443188 SCOPUS ID: 2-s2.0-85115168052 09/16/2021
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology.

(Hall WA, Kamgar M, Erickson BA, Ponce SB, Tsai S, Nevalainen MT, Christians KK, George B, Dua KS, Khan AH, Evans DB, Azmi AS.) Cancer Metastasis Rev. 2021 09;40(3):879-889 PMID: 34611794 PMCID: PMC8767496 SCOPUS ID: 2-s2.0-85116412346 10/07/2021
Second-generation jak2 inhibitors for advanced prostate cancer: Are we ready for clinical development?

(Beinhoff P, Sabharwal L, Udhane V, Maranto C, Laviolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT.) Cancers. October-2 2021;13(20) SCOPUS ID: 2-s2.0-85117018634 10/01/2021
Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo.

(Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT.) Cancers (Basel). 2020 Nov 18;12(11) PMID: 33217941 PMCID: PMC7724566 SCOPUS ID: 2-s2.0-85096199725 11/22/2020
Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy.

(Hall WA, Sabharwal L, Udhane V, Maranto C, Nevalainen MT.) Int J Biochem Cell Biol. 2020 10;127:105827 PMID: 32822847 PMCID: PMC8638530 SCOPUS ID: 2-s2.0-85090734995 08/22/2020
Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network.

(Bukowy JD, Foss H, McGarry SD, Lowman AK, Hurrell SL, Iczkowski KA, Banerjee A, Bobholz SA, Barrington A, Dayton A, Unteriner J, Jacobsohn K, See WA, Nevalainen MT, Nencka AS, Ethridge T, Jarrard DF, LaViolette PS.) J Med Imaging (Bellingham). 2020 Sep;7(5):057501 PMID: 33062803 PMCID: PMC7550797 10/17/2020
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

(Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT.) Mol Cancer Ther. 2020 01;19(1):231-246 PMID: 31548294 PMCID: PMC6946850 SCOPUS ID: 2-s2.0-85077669370 09/25/2019
Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

(Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT.) Cancer Epidemiol Biomarkers Prev. 2019 10;28(10):1642-1651 PMID: 31292140 PMCID: PMC6774884 SCOPUS ID: 2-s2.0-85072849403 07/12/2019
Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space.

(McGarry SD, Bukowy JD, Iczkowski KA, Unteriner JG, Duvnjak P, Lowman AK, Jacobsohn K, Hohenwalter M, Griffin MO, Barrington AW, Foss HE, Keuter T, Hurrell SL, See WA, Nevalainen MT, Banerjee A, LaViolette PS.) Tomography. 2019 03;5(1):127-134 PMID: 30854450 PMCID: PMC6403022 SCOPUS ID: 2-s2.0-85071529534 03/12/2019

Marja T. Nevalainen, MD, PhD